StockData
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc. (GDRX) stock

GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3037% below fair value
$3.47−0.04 (-1.14%)

Close on Nov 17, 2026Market cap $1.18BP/E 86.8Yield –

Earnings

GoodRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 3, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$200.40M
-1.3% on a year earlier
Adjusted Earnings Per Share Diluted, Q2 FY2026
$0.08
$0.09 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of GoodRx's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 3, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$200.40M-1.3%$0.02$0.08Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$194.00M-4.4%––Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close$194.80M-1.9%$0.02$0.09Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$196.00M+0.4%$0.00$0.08Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$203.10M+1.2%$0.04$0.09Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close$203.00M+2.6%$0.03$0.09Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$198.60M+1.0%$0.02$0.09Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$195.30M+8.5%$0.01$0.08Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$200.60M+5.7%$0.02$0.08Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$197.90M+7.6%$0.00$0.08Release
Q4 FY2023ended Dec 31, 2023Feb 29, 2024before the open$196.60M+6.8%-$0.06$0.08Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

GoodRx's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2026$790.00M – $805.00M$765.00M – $785.00MRaisedAug 5, 2026
Adjusted EBITDAnon-GAAPFY2026$240.00M – $250.00M$235.00MRaisedAug 5, 2026
Revenue YoY ChangeFY2026-6% – -2%–NewFeb 25, 2026

Guidance vs results

The last range GoodRx gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue growth+35%+0.57%Σ4QBelow range
Q1 FY2025Revenue$201.00M – $205.00M$203.00MWithin range
Q4 FY2024Revenue$200.00M$198.60MBelow range
Q3 FY2024Revenue$193.00M – $197.00M$195.30MWithin range
Q2 FY2024Revenue$200.00M$200.60MAbove range
Q4 FY2023Revenue$195.00M – $197.00M$196.60MWithin range
Q3 FY2023Revenue$186.00M – $190.00M$180.00MBelow range
Q2 FY2023Revenue$185.00M – $188.00M$189.70MAbove range
Q1 FY2023Revenue$181.00M – $183.00M$184.00MAbove range
Q4 FY2022Revenue$175.00M – $180.00M$184.10MAbove range

Guidance history

Every forecast GoodRx put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Adjusted EBITDAFY2026$240.00M – $250.00MRaised
Aug 5, 2026RevenueFY2026$790.00M – $805.00MRaised
May 6, 2026Adjusted EBITDAFY2026$235.00MRaised
May 6, 2026RevenueFY2026$765.00M – $785.00MRaised
Feb 25, 2026Adjusted EBITDAFY2026$230.00MNew
Feb 25, 2026Revenue YoY ChangeFY2026-6% – -2%New
Feb 25, 2026RevenueFY2026$750.00M – $780.00MNew
Nov 4, 2025Adjusted EBITDA YoY ChangeFY2025+2% – +6%New
Nov 4, 2025Adjusted EBITDAFY2025$265.00M – $275.00MNew
Nov 4, 2025Pharma Manufacturer Solutions Revenue Outlook Year-Over-Year GrowthFY2025+35%New
Aug 6, 2025Adjusted EBITDA YoY ChangeFY2025+2% – +6%Lowered
Aug 6, 2025Adjusted EBITDAFY2025$265.00M – $275.00MLowered
May 7, 2025Adjusted EBITDA YoY ChangeFY2025+5% – +10%New
May 7, 2025Adjusted EBITDAFY2025$273.00M – $287.00MRaised
May 7, 2025Revenue YoY ChangeFY2025+2% – +6%New
May 7, 2025RevenueFY2025$810.00M – $840.00MNew
Feb 27, 2025Adjusted EBITDAFY2025$270.00M – $286.00MNew
Feb 27, 2025Adjusted EBITDA MarginQ1 FY202533%New
Feb 27, 2025RevenueQ1 FY2025$201.00M – $205.00MNew
Feb 27, 2025RevenueFY2025$810.00M – $840.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases GoodRx filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Update
  13. Results
  14. Update
  15. Results

See a number that looks wrong?